Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
As part of the deal, Sarepta picks up five gene therapy candidates to treat distinct types of LGMD. The original deal was inked in May 2018, when the two companies partnered to develop five gene therapy compounds.
Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN
The past year, 2018, was in many ways a decisive year for Promore Pharma
Genovis has chosen to apply IFRS 16 in advance, as well as the simplification rule regarding short-term leases.
Ultragenyx Pharmaceutical Inc. announced that it has commenced an underwritten public offering of up to $250,000,000 of shares of its common stock.
Microbix Biosystems Inc., an innovator of biological products and technologies, announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.
Shares of General Electric jumped as much as 13 percent in trading this morning after Danaher Corporation announced it was acquiring the conglomerate’s biopharma business, GE Biopharma, for $21.4 billion.
This morning, Ipsen said it entered into an agreement with Clementia will help the company continue its transformation that is part of a key strategic objective to accelerate its rare disease pipeline.
Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics, said his company is the only biotech company that has successfully commercialized a gene therapy for a genetic disease in the United States.
FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability